14. The MME (Morphine Milligram Equivalent) per day limit that typically requires justification to states and insurance payers before approval is:
A. 25 MME/Day. B. 40 MME/Day. C. 75 MME/Day. D. 90 MME/Day.
15. Benefits of using buprenorphine in the treatment of OUD include: A. Ease of administration. B. Low risk for respiratory depression. C. Ability to use protocol dosing using the COWS (Clinical Opiate Withdrawal Scale). D. All of the above. 16. The number of lives lost to drug overdose in 2021 was found to be
A. About 10,000 lives. B. About 30,000 lives. C. Just under 70,000 lives. D. Over 100,000 lives.
17. Buprenorphine is an opioid __________. A. Full agonist. B. Partial agonist. C. Antagonist. D. Receptor Type.
18. Regarding opioid use disorder: A. Physical dependency can develop after 2-10 days of continuous use. B. Opioid related overdose death is largely attributed to fentanyl. C. Can be associated with biological and environmental factors. D. All of the above. 19. The following patient education topics should be discussed with patients who are prescribed opioid medications. A. Education regarding the use of naloxone (Narcan).
B. Secure storage of the drug. C. Proper disposal of the drug. D. All of the above.
20. The prevalence of substance use disorder (SUD) in physicians is estimated to be about:
A. 10%. B. 20%. C. 30%. D. 40%
44
Powered by FlippingBook